Show simple item record

dc.contributor.authorNieder, Carsten
dc.contributor.authorHaukland, Ellinor Christin
dc.contributor.authorMannsåker, Bård
dc.contributor.authorPawinski, Adam
dc.contributor.authorYobuta, Rosalba
dc.contributor.authorNorum, Jan
dc.date.accessioned2020-03-30T13:40:19Z
dc.date.available2020-03-30T13:40:19Z
dc.date.issued2019
dc.description.abstract<b>Background/Aim</b>: Compared to intravenous taxane chemotherapy, newer orally-available and/or less toxic agents for metastatic castration-resistant prostate cancer (MCRPC) may be associated with higher likelihood of starting treatment in patients with adverse prognostic features and limited life expectancy. To test this hypothesis, we analyzed the rates of treatment initiation during the last 30 days of life in a real-world cohort of men with MCRPC. Patients and Methods: This was a retrospective analysis of 146 patients. <b>Results</b>: Seven patients (5%) who started any systemic treatment during the last 30 days of life were identified. The likelihood of treatment initiation in the last 30 days of life correlated significantly with the number of lines of systemic treatment (higher risk for previously treated patients) and non-use of bone-targeted agents. <b>Conclusion</b>: Initiation of systemic therapy in the last 30 days of life was uncommon. This endpoint might complement other quality-of-care indicators.en_US
dc.identifier.citationNieder, C.; Haukland, E.; Mannsåker, B.; Pawinski, A.; Yobuta, R.; Norum, J.N.(2019) Initiation of systemic therapy during the last 30 days of life in patients with metastatic castration-resistant prostate cancer. <i>Anticancer Research, 39, </i>(1), 335-340en_US
dc.identifier.cristinIDFRIDAID 1691971
dc.identifier.doi10.21873/anticanres.13116
dc.identifier.issn0250-7005
dc.identifier.issn1791-7530
dc.identifier.urihttps://hdl.handle.net/10037/17920
dc.language.isoengen_US
dc.publisherThe International Institute of Anticancer Researchen_US
dc.relation.journalAnticancer Research
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright© 2019, International Institute of Anticancer Researchen_US
dc.titleInitiation of systemic therapy during the last 30 days of life in patients with metastatic castration-resistant prostate canceren_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record